key: cord-0958966-dj0250mb authors: Baldrick, Paul title: Development of COVID-19 therapies: Nonclinical testing considerations date: 2022-05-21 journal: Regul Toxicol Pharmacol DOI: 10.1016/j.yrtph.2022.105189 sha: 998d960c3e24d6cedfca584ff55b5c280e482489 doc_id: 958966 cord_uid: dj0250mb Therapies have been developed in the last couple of years to allow vaccination against, or treatment of patients with, COVID-19 using pathways such as Emergency Use Authorization (EUA) in the USA and Conditional Marketing Authorization (CMA) in the EU and UK. However, nonclinical studies were performed to allow such authorization and these were reviewed for 6 vaccines, 7 biological (monoclonal antibodies [mAbs]) and 4 small molecule therapies to examine whether the number and types of studies normally needed for regulatory agency authorization have been reduced. Results showed that the short answer is generally no. Thus, a battery of immunogenicity/efficacy or related pharmacology/biological activity studies showing utility against SARS-CoV-2 were performed as well as general toxicity studies across all 3 compound classes along with pharmacokinetic studies for mAbs and small molecules and, reproduction toxicity testing for vaccines and small molecules; additionally, genotoxicity testing occurred for small molecules. What was different from conventional, lengthy drug development, was that for vaccines and small molecules, leverage to existing platform technology or data available for other development programs, respectively, occurred. Recognition that mAbs can target the spike protein leading to neutralization allowed rapid development into clinical candidates. studies obviating the need for separate local tolerance work. Consistent with the protein nature of cynomolgus monkeys as well. Vaccines were evaluated for VAERD with no evidence for an exacerbation of respiratory disease, measured indirectly from Th1 skewing or from lung 227 histopathology in efficacy models. It is unclear why safety pharmacology testing (a cardiovascular 228 and respiratory study in mice) occurred for one vaccine but this may have occurred to satisfy a 229 specific requirement for development of vaccines in Japan, where guidance requires strong 230 justification for not performing stand-alone safety pharmacology studies (Sun et al., 2012) . Although not necessarily a feature of vaccine development, some form of biodistribution 232 evaluation occurred among the vaccines looking at distribution after IM dosing and in 3 cases 233 involved reference to studies with a related platform or vaccine construct. Additionally, specific 234 biodistribution testing occurred for novel excipient constituents for 2 vaccines and was planned at The nonclinical testing package for mAbs used for treatment after COVID-19 is shown in Table 256 2. All but one of them had no previous authorized use, while one (tocilizumab) already had 257 marketing approval for another indication and reference was made to the existing nonclinical 258 studies (it was therefore excluded for comparison of studies used for authorization of the remaining 259 6 products). In addition, 3 products involved use of a "cocktail" of 2 mAbs together (binding to 260 different epitopes of the RBD of SARS-CoV-2). Overall, testing was consistent with guideline battery (the significance of this situation will be discussed later). The 3 products involving use of 269 2 mAbs tended to be evaluated either alone or administered together. As for vaccine testing were well tolerated with no adverse findings seen. As per regulatory guidance, tissue cross 294 J o u r n a l P r e -p r o o f reactivity testing (generally in human adult and fetal tissue) was performed for all the 6 mAb products, with no binding of clinical concern seen. 296 The nonclinical testing package for the 4 small molecules used for treatment after COVID-19 is 297 shown in Table 3 . The pathway to authorization appears to have been different from the vaccines 298 and mAbs described above as the compounds had been in development in the past or had marketing 299 approval for other indications. Reference was made to the existing nonclinical studies as well as 300 performance of new pharmacology/biological activity studies for the 3 antiviral products. The 301 latter studies included antiviral testing using in vitro assays as well as administration in mouse (2 302 products) or rhesus monkey (one product) models of SARS-CoV-2 infection. Remaining 303 nonclinical testing was of a conventional nature for a small molecule and included safety 304 pharmacology, ADME, 2 species general toxicity, reproduction toxicity and genotoxicity studies. Furthermore, a much more extensive package of studies was available for the 4 th product, the janus 306 kinase inhibitor baricitinib to support its marketed use for rheumatoid arthritis (due to the chronic 307 nature of this disease, the package included chronic duration toxicity studies and carcinogenicity 308 testing no evidence for concern for VAERD was seen • Reproduction toxicity battery of fertility and early embryonic toxicity study in rats, embryo-fetal development study in rats and rabbits and pre-and post-natal development study in rats: main findings were reduction in number of corpora lutea, implantation sites and viable embryos, and lower mean ovary and uterus/cervix/oviduct weights in fertility and early embryonic toxicity study along with maternal toxicity in this and rabbit embryo-fetal development study • ADME package of studies including drug-drug interaction evaluation • Pivotal oral toxicity study of 28 days or 3 months in rat and dogs with molnupiravir; in 28-day dog study, bone marrow changes affecting all hematopoietic cell lines and causing subsequent hematological abnormalities including severe thrombocytopenia was seen and in 3month rat study, abnormal bone (growth plate) and cartilage formation were noted (not seen in 28-day study giving similar exposure but in older rats) • Reproductive toxicity studies included fertility in rats, embryo-fetal development studies in rats and rabbits and a pre-and postnatal development study in rats with molnupiravir; in embryo-fetal development, delayed and incomplete ossification in fetuses was noted along with (in the presence of maternal toxicity) high dose embryo-fetal lethality and teratogenicity and reduced fatal growth in rats and reduced fetal body weights [Based on general and reproduction toxicity study findings, molnupiravir was not authorized for use in patients less than 18 years old (juvenile toxicity study in rats was planned to further examine bone/cartilage formation-related findings)] • Molnupiravir and its metabolite NHC were positive for mutagenicity in in vitro Ames assays, molnupiravir gave a negative result in in vitro and in vivo rat micronucleus tests, an equivocal result in a rat Pig-a assay but was negative in transgenic Big Blue ® rat assay (Based on the weight of evidence and expert input as well as the short-term use, risk of mutagenicity following treatment was considered to be low; however, a transgenic rodent male germ cell mutagenicity assay is planned) Paxlovid (nirmatrelvir = • Core battery safety pharmacology testing including hERG channel inhibition potential, cardiovascular assessment in cynomolgus monkeys plus CNS and respiratory studies in rats (with additional ion channel evaluation and guinea pig isolated Langendorff-perfused heart model and rat isolated ascending aorta tissue studies) with nirmatrelvir: some minor effects were seen in CNS, respiratory and cardiovascular parameters but are monitorable in clinic and had no correlating findings were seen in toxicity testing • ADME with nirmatrelvir included single dose PK studies in rats and monkeys, plasma protein binding, liver microsome and hepatocyte studies (and in vivo metabolite examination in rats and monkeys) along with evaluation of excretion in rats and monkeys • Toxicology testing comprised 4-day range-finders plus 2-week and 4- week GLP studies in rats and cynomolgus monkeys with nirmatrelvir: 2-week toxicity studies produced recoverable hematology and coagulation findings in rats and increased fibrinogen in cynomolgus monkeys that had no clinical or microscopic correlations in rats and were therefore not considered adverse; recoverable hepatocellular hypertrophy consistent with microsomal enzyme induction and associated with thyroid follicular cell hypertrophy were seen in rats and considered non-adverse. 4-week studies confirmed a lack of toxicity • Other than some minor bodyweight changes, no reproduction toxicity was seen in studies of fertility and early embryo developmental in rats, embryo and fetal developmental effects in rats and rabbits and pre-and • Nonclinical studies to allow authorization of COVID-19 therapies were examined • Included 5 vaccines, 7 monoclonal antibodies and 4 small molecule therapies • "Standard" studies to allow clinical use were largely preformed • However, examples of "speeded up